Market Place
Sourcing Support
enGene Announces Name Change to enGene Therapeutics
07 Apr 2026 //
PHARMIWEB
Engene To Join Guggenheim Biotech Summit 2026
04 Feb 2026 //
PHARMIWEB
enGene Expands Debt Facility To $125M With Hercules Capital
20 Jan 2026 //
BUSINESSWIRE
Engene Reports 2025 Financial Results And Business Update
22 Dec 2025 //
BUSINESSWIRE
enGene`s Detalimogene Chosen For FDA Manufacturing Pilot Program
02 Dec 2025 //
BUSINESSWIRE
Engene To Present At Piper Sandler Healthcare Conference
25 Nov 2025 //
BUSINESSWIRE
Detalimogene Shows 62% Complete Response Rate At 6 Months
11 Nov 2025 //
BUSINESSWIRE
enGene To Host Conference Call On Pivotal Cohort of LEGEND Trial
10 Nov 2025 //
BUSINESS WIRE
Engene To Join Investor Conferences
06 Nov 2025 //
BUSINESSWIRE
Engene Names Hussein Sweiti, M.d., Msc Chief Medical Officer
30 Sep 2025 //
BUSINESSWIRE
enGene Q3 2025 Financial Results and Business Update
11 Sep 2025 //
PHARMAWEB
enGene Appoints New Board and Leadership for Commercial Readiness
08 Jul 2025 //
BUSINESSWIRE
FDA Grants RMAT for enGene’s Detalimogene for Bladder Cancer
25 Jun 2025 //
BUSINESSWIRE
enGene to Participate in Upcoming Investor Conferences
28 Apr 2025 //
BUSINESSWIRE
enGene Reports Q1 2025 Financial Results and Business Update
10 Mar 2025 //
BUSINESSWIRE
enGene To Join Leerink Partners Global Healthcare Conference
04 Mar 2025 //
BUSINESSWIRE
enGene to Present at Oppenheimer 35th Annual Healthcare Conference
04 Feb 2025 //
BUSINESSWIRE
enGene Reports Inducement Grants Under NASDAQ LR 5635(c)(4)
30 Dec 2024 //
BUSINESSWIRE
enGene to Participate in Upcoming Investor Conferences
25 Nov 2024 //
BUSINESSWIRE
enGene to Participate in Guggenheim Health Innovation Conference
05 Nov 2024 //
BUSINESSWIRE
enGene Announces $60 Million Private Placement Financing
25 Oct 2024 //
BUSINESSWIRE
enGene Reports Inducement Grant Under NASDAQ Rule
22 Oct 2024 //
BUSINESSWIRE
enGene Reports Q3 2024 Results And Business Update
10 Sep 2024 //
BUSINESSWIRE
enGene to Participate in Upcoming Investor Conferences
28 Aug 2024 //
BUSINESSWIRE
enGene drops cystic fibrosis program to focus on bladder cancer
14 Jun 2024 //
FIERCE BIOTECH
enGene To Present LEGEND Phase 1/2 Bladder Cancer Data At AUA
02 May 2024 //
PR NEWSWIRE
enGene Hires Dr. Pruthi As Urologic Oncology SVP
09 Apr 2024 //
PR NEWSWIRE
enGene Announces Leadership Succession Plan
14 Feb 2024 //
PR NEWSWIRE
enGene Announces Oversubscribed $200 Million Private Placement Financing
14 Feb 2024 //
PR NEWSWIRE
enGene Announces Expanded $50 Million Debt Facility with Hercules Capital
22 Dec 2023 //
PR NEWSWIRE
enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors
19 Dec 2023 //
PR NEWSWIRE
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
01 Nov 2023 //
PR NEWSWIRE
enGene starts trading on Nasdaq after completing Forbion SPAC deal
01 Nov 2023 //
ENDPTS
SPAC in business: Gene therapy biotech takes blank-check route
17 May 2023 //
FIERCE BIOTECH
